SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?

Seeking Alpha17:32 ET

Best Income Ideas for 2025: Stocks, Bonds, and Everything in Between

BarronsJan 3 15:14 ET

GSK Gets Approval in China for Nucala for Rhinosinusitis

Seeking AlphaJan 3 09:21 ET

GSK Wins Chinese Nod for Nucala as Chronic Rhinosinusitis Treatment

MT NewswiresJan 3 02:20 ET

GSK (GSK.US) "Mubilizumab" has been approved for a new indication in China.

Chronic sinusitis accompanied by nasal polyps is a chronic inflammatory disease of the nasal cavity or sinuses, which can lead to the growth of soft tissues known as nasal polyps, usually characterized by an increase in eosinophil levels.

Zhitong FinanceJan 2 08:22 ET

GlaxoSmithKline (GSK.US) has submitted for the market approval of its ultra-long-acting IL-5 monoclonal antibody in China.

The CDE website shows that GlaxoSmithKline (GSK.US) has applied for the market launch of depemokimab in the country.

Zhitong FinanceJan 1 05:50 ET